File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effectiveness of Ribavirin and Corticosteroids for Severe Acute Respiratory Syndrome

TitleEffectiveness of Ribavirin and Corticosteroids for Severe Acute Respiratory Syndrome
Authors
Issue Date2009
PublisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/amj
Citation
American Journal Of Medicine, 2009, v. 122 n. 12, p. 1150.e11-1150.e21 How to Cite?
AbstractObjective: Ribavirin and corticosteroids were used widely as front-line treatments for severe acute respiratory syndrome; however, previous evaluations were inconclusive. We assessed the effectiveness of ribavirin and corticosteroids as the initial treatment for severe acute respiratory syndrome using propensity score analysis. Methods: We analyzed data on 1755 patients in Hong Kong and 191 patients in Toronto with severe acute respiratory syndrome using a generalized propensity score approach. Results: The adjusted excess case fatality ratios of patients with severe acute respiratory syndrome receiving the combined therapy of ribavirin and corticosteroids within 2 days of admission, compared with those receiving neither treatment within 2 days of admission, were 3.8% (95% confidence interval, -1.5 to 9.2) in Hong Kong and 2.1% (95% confidence interval, -44.3 to 48.5) in Toronto. Conclusions: Our results add strength to the hypothesis that the combination of ribavirin and corticosteroids has no therapeutic benefit when given early during severe acute respiratory syndrome infection. Further studies may investigate the effects of these treatments later in disease course. © 2009 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/86761
ISSN
2015 Impact Factor: 5.61
2015 SCImago Journal Rankings: 2.023
ISI Accession Number ID
Funding AgencyGrant Number
Food and Health Bureau of the Hong Kong Special Administrative Region GovernmentHKU-AA-018
Canadian Institutes for Health Research
Funding Information:

This work was supported in part through a research grant from the Research Fund for the Control of Infectious Diseases of the Food and Health Bureau of the Hong Kong Special Administrative Region Government (grant no. HKU-AA-018) and by the Canadian Institutes for Health Research.

References

 

DC FieldValueLanguage
dc.contributor.authorLau, EHYen_HK
dc.contributor.authorCowling, BJen_HK
dc.contributor.authorMuller, MPen_HK
dc.contributor.authorHo, LMen_HK
dc.contributor.authorTsang, Ten_HK
dc.contributor.authorLo, SVen_HK
dc.contributor.authorLouie, Men_HK
dc.contributor.authorLeung, GMen_HK
dc.date.accessioned2010-09-06T09:21:00Z-
dc.date.available2010-09-06T09:21:00Z-
dc.date.issued2009en_HK
dc.identifier.citationAmerican Journal Of Medicine, 2009, v. 122 n. 12, p. 1150.e11-1150.e21en_HK
dc.identifier.issn0002-9343en_HK
dc.identifier.urihttp://hdl.handle.net/10722/86761-
dc.description.abstractObjective: Ribavirin and corticosteroids were used widely as front-line treatments for severe acute respiratory syndrome; however, previous evaluations were inconclusive. We assessed the effectiveness of ribavirin and corticosteroids as the initial treatment for severe acute respiratory syndrome using propensity score analysis. Methods: We analyzed data on 1755 patients in Hong Kong and 191 patients in Toronto with severe acute respiratory syndrome using a generalized propensity score approach. Results: The adjusted excess case fatality ratios of patients with severe acute respiratory syndrome receiving the combined therapy of ribavirin and corticosteroids within 2 days of admission, compared with those receiving neither treatment within 2 days of admission, were 3.8% (95% confidence interval, -1.5 to 9.2) in Hong Kong and 2.1% (95% confidence interval, -44.3 to 48.5) in Toronto. Conclusions: Our results add strength to the hypothesis that the combination of ribavirin and corticosteroids has no therapeutic benefit when given early during severe acute respiratory syndrome infection. Further studies may investigate the effects of these treatments later in disease course. © 2009 Elsevier Inc. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/amjen_HK
dc.relation.ispartofAmerican Journal of Medicineen_HK
dc.subject.meshAdrenal Cortex Hormones - therapeutic useen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshCanada - epidemiologyen_HK
dc.subject.meshCohort Studiesen_HK
dc.subject.meshDrug Administration Scheduleen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshHong Kong - epidemiologyen_HK
dc.subject.meshHospitalizationen_HK
dc.subject.meshHumansen_HK
dc.subject.meshL-Lactate Dehydrogenaseen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPropensity Scoreen_HK
dc.subject.meshRespiratory Distress Syndrome, Adult - drug therapy - mortalityen_HK
dc.subject.meshRetrospective Studiesen_HK
dc.subject.meshRibavirin - therapeutic useen_HK
dc.subject.meshSeverity of Illness Indexen_HK
dc.titleEffectiveness of Ribavirin and Corticosteroids for Severe Acute Respiratory Syndromeen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0002-9343&volume=122&issue=12&spage=1150.e21&epage=&date=2009&atitle=Effectiveness+of+ribavirin+and+corticosteroids+for+Severe+Acute+Respiratory+Syndromeen_HK
dc.identifier.emailLau, EHY:ehylau@hku.hken_HK
dc.identifier.emailCowling, BJ:bcowling@hku.hken_HK
dc.identifier.emailHo, LM:lmho@hkucc.hku.hken_HK
dc.identifier.emailLeung, GM:gmleung@hku.hken_HK
dc.identifier.authorityLau, EHY=rp01349en_HK
dc.identifier.authorityCowling, BJ=rp01326en_HK
dc.identifier.authorityHo, LM=rp00360en_HK
dc.identifier.authorityLeung, GM=rp00460en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.amjmed.2009.07.018en_HK
dc.identifier.pmid19958895-
dc.identifier.scopuseid_2-s2.0-72049083215en_HK
dc.identifier.hkuros168291en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-72049083215&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume122en_HK
dc.identifier.issue12en_HK
dc.identifier.spage1150.e11en_HK
dc.identifier.epage1150.e21en_HK
dc.identifier.eissn1555-7162-
dc.identifier.isiWOS:000272333700024-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLau, EHY=7103086074en_HK
dc.identifier.scopusauthoridCowling, BJ=8644765500en_HK
dc.identifier.scopusauthoridMuller, MP=7404688353en_HK
dc.identifier.scopusauthoridHo, LM=7402955625en_HK
dc.identifier.scopusauthoridTsang, T=7101832378en_HK
dc.identifier.scopusauthoridLo, SV=8426498400en_HK
dc.identifier.scopusauthoridLouie, M=7006128942en_HK
dc.identifier.scopusauthoridLeung, GM=7007159841en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats